Related Experiment Video

Updated: Apr 20, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

Old drug, new trick: repurposing metformin for gynecologic cancers?

Terri Febbraro1, Ernst Lengyel1, Iris L Romero1

  • 1Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA.

Gynecologic Oncology
|December 3, 2014
PubMed
Abstract

Insights

Metformin, a diabetes drug, shows promise in fighting gynecologic cancers by inhibiting cancer cell growth through molecular pathways. Clinical studies suggest benefits for diabetic women, but its effectiveness in non-diabetic patients requires further investigation.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Metformin is a widely prescribed antidiabetic medication.
  • Emerging evidence suggests metformin possesses anticancer properties.
  • Gynecologic cancers, including endometrial, ovarian, and cervical cancers, are significant health concerns.

Purpose of the Study:

  • To review the molecular mechanisms of metformin's anticancer effects.
  • To summarize preclinical and clinical evidence of metformin's potential in gynecologic cancer.
  • To assess metformin's role in cancer prevention and treatment.

Main Methods:

  • A comprehensive literature search was performed using PubMed.
  • Keywords included "metformin" combined with gynecologic cancer-related terms.
  • Studies published in English from 1994 to 2014 were included.

Main Results:

  • Preclinical studies indicate metformin inhibits growth in endometrial, ovarian, and cervical cancer cells.
  • Metformin's primary mechanism involves activating AMP-activated protein kinase (AMPK) and inhibiting mTOR.
  • Clinical data suggest metformin use is linked to reduced cancer risk and improved survival in diabetic women with ovarian and endometrial cancers.

Conclusions:

  • Clinical studies associate metformin use in diabetic patients with better gynecologic cancer outcomes.
  • Plausible biological mechanisms support metformin's anticancer activity.
  • The efficacy of metformin in non-diabetic cancer patients remains theoretical and requires prospective clinical trials.
Keywords:
Endometrial cancerGlucoseGynecologic cancerMetforminOvarian cancer

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000